Microglial chemotactic signaling factors in Alzheimer’s disease

American Journal of Neurodegenerative Diseases

Volumn 1, Issue 3, 2012, Pages 199-204

  McLarnon, James G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AD animal models; Alzheimer s disease (AD); Chemotactic factors; Inflammatory responses; Microglial chemotaxis

Indexed keywords

AMYLOID BETA PROTEIN; CHEMOTACTIC PEPTIDE; ENHANCED GREEN FLUORESCENT PROTEIN; FRACTALKINE; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ALZHEIMER DISEASE; CELL MIGRATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOREACTIVITY; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; REVIEW; VASCULAR REMODELING;

EID: 84980053724     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Akiyama H, Burger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss- Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
2. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-318.
3. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011; 91: 461-553.
4. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. Glia 2002; 40: 260-269.
5. Wyss-Corey T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response. Nature Medicine 2006; 12: 1005- 1015.
6. Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 2002; 132: 93-98.
7. Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. J Neurosci 2009; 29: 3-13.
8. Xia M, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J NeuroVirology 1999; 5: 32-41.
9. Mattiace LA, Davies P, Dickson DW. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol 1990; 36: 1101-1114.
10. Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001; 22: 945-956.
11. Rogers J, Lue LF. Microglial chemotaxis, activation and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39: 333-340.
12. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998; 152: 307-317.
13. Meyer-Luchmann M, Soires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-724.
14. 1-42)- induced expression and production of proinflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 2005; 159: 66-74.
15. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25: 8240-8249.
16. Meda L, Bernasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos LJ, Mantovani A, Rossi F, Cassatella MA. Beta amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol 1996; 157: 1213-1218.
17. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented microglia in vitro. Glia 2001; 35: 72-79.
18. Ishizuka K, Kimura T, Igata-Yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry and Clinical Neurosci 1997; 51: 135-138.
19. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001; 22: 957-966.
20. Galimberti D, Schoonerboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer's disease. Arch Neural 2006; 63: 538- 543.
21. Janelsins M, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflamm 2005; 2: 23.
22. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/ CCL2 in β-amyloid precursor protein mice show accelerated diffuse β-amyloid deposition. Am J Pathol 2005; 166: 1475-1485.
23. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009; 19: 392-398.
24. Xia M, Qin S, Wu L, Mackay CR, Hyman BT. Immunohistochemical study of the β- chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998; 53: 31-37.
25. swe transgenic mice. Neurochem Res 2008; 33: 1085- 1089.
26. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, Lee CU. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2008; 436: 196-200.
27. D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging 2004; 25: 675-683.
28. Desforges NM, Hebron ML, Algarzae NK, Lonskaya I, Moussa CEH. Fractalkine mediates communication between pathogenic proteins and microglia: Implications of anti-inflammatory treatments in different stages of neurodegenerative diseases. Int J Alz Dis 2012; 1-9.
29. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271: 603-606.
30. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental ischemia. Brain Res Mol Brain Res 1998; 62: 101-105.
31. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237- 243.
32. Ryu JK, Cho T, Wang YT, Mclarnon JG. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. J Neuroinflamm 2009; 6: 39.
33. Widera D, Holtkamp W, Entschladen F, Niggemann B, Zanker K, Kaltschmidt B, Kaltschmidt C. MCP-1 induced migration of adult neural stem cells. Eur J Cell Biol 2004; 83: 381-387.